This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Apomorphine

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Apomorphine is a dopamine agonist. It is given by subcutaneous injection or by pump in exceptional cases in certain specialist centres. It acts by stimulating post-synaptic dopamine receptors and is very effective in severe disease refractory to other treatments.

NICE guidance states (1):

  • intermittent apomorphine injections may be used to reduce off time in people with Parkinson's disease (PD) with severe motor complications
  • continuous subcutaneous infusions of apomorphine may be used to reduce off time and dyskinesia in people with PD with severe motor complications. Its initiation should be restricted to expert units with facilities for appropriate monitoring

Reference:

  1. NICE (June 2006). Parkinson's disease

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.